Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD44v6 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD44v6 monoclonal antibody is an immunotherapeutic agent targeting the CD44v6 splice variant, which is specifically expressed on acute myeloid leukemia (AML) cells but minimally on normal hematopoietic stem cells. CD44v6 promotes AML progression and chemoresistance (to Ara-C and Venetoclax) by driving a transcriptional program through a CD44v6-SPP1 autocrine loop. This signaling axis activates the MAPK/DUSP pathways and shifts anti-apoptotic dependence toward MCL-1 and BCL-XL. Blockade with a CD44v6 monoclonal antibody has been shown to partially reverse these pro-survival effects in preclinical models, making it a promising target for overcoming resistance in high-risk AML.
- Other names
- anti-CD44v6 antibodyanti-CD-44v6 antibodyanti-CD 44v6 antibodyanti-CD44v6 monoclonal antibodyanti-CD-44v6 monoclonal antibodyanti-CD 44v6 monoclonal antibody
02
Targets
CD44v6 (CD44 variant isoform 6)
Beyond the preview
Go deeper on CD44v6 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD44v6 monoclonal antibody.